Loading…
for educational and safety purposes
sci-wiki~$open stack nefiracetammed
nefiracetam with the layers usually stacked around it, and a straight account of which of those pairings anyone has actually studied
9 items; 8 structures drawn from pubchem, 1 drawn generically because pubchem has no record of the name.
Nefiracetam is the most interesting racetam on this site and the owner is right to build around it. Its pharmacology is unusually well characterised for the class: it potentiates nicotinic and NMDA currents on a bell-shaped curve that peaks at nanomolar concentrations, enhances long-term potentiation through CaMKII, and does it through the glycine site rather than by brute agonism.
What the surrounding layers do not have is evidence of being layers. Every pairing in the brief was checked: nefiracetam has never been studied with DHA, with phosphatidylserine, with a PDE4 inhibitor, with magnesium, with aniracetam, or with any choline source. Not one of those combinations has been tested by anyone. That does not make them wrong; it makes them untested, and the difference matters on a page someone reads before spending money.
Three of the brief's mechanisms are actively backwards, and they are corrected in the roles above rather than repeated. The most useful is the magnesium one: the brief's own premise, that nefiracetam reduces the magnesium block, is the correct finding, and it is exactly the reason supplementing magnesium works against the mechanism instead of supporting it.
The honest version of the layering is narrower than the brief's but it is not empty.
Choline and nefiracetam is the pairing with the best rationale even though the depletion story is wrong, because a cholinergic compound and a cholinergic substrate is ordinary biochemistry rather than a claim.
Aniracetam and nefiracetam genuinely do not overlap: nefiracetam leaves AMPA currents alone at its active concentration, so an AMPA-targeting compound occupies a different site. That is non-redundancy, which is a real reason to combine two things, and it is a weaker claim than synergy.
Tropisetron and nefiracetam do NOT meet at the nicotinic receptor. Nefiracetam works at alpha-4-beta-2 and leaves alpha-7 almost unaffected; tropisetron is an alpha-7 partial agonist. Both are worth taking on their own merits and the story about them converging is not true.
Nefiracetam is reported as smooth and slow rather than acute, and the bell-shaped dose response is the practical thing to know about it: more is not better, and past its peak the effect falls away. That is unusual enough that people who treat it like a stimulant tend to conclude it does nothing.
NEFIRACETAM HAS REAL PUBLISHED ANIMAL TOXICOLOGY AND IT IS WORTH READING PROPERLY RATHER THAN DISMISSING. In beagles at 180 to 300 mg/kg daily, testicular testosterone fell within four hours of a single dose, and at four weeks there was moderate to severe seminiferous atrophy with multinucleated giant cells, reduced sperm motility and increased malformed sperm. Separately, at 300 mg/kg for eleven weeks dogs developed renal papillary necrosis. AND THE COMMON REASSURANCE ABOUT THIS IS ONLY HALF TRUE. The RENAL finding is explicitly argued to be dog-specific, driven by a metabolite concentrating in the papilla plus dogs' unusually low papillary prostaglandin synthesis, and rats and monkeys did not show it. The TESTICULAR paper makes no species-specificity claim at all; it proposes a Leydig-cell steroidogenesis mechanism and does not exempt anyone. The doses are far above human trial doses, roughly 180 to 300 mg/kg against 10 to 15, which mitigates and does not erase, because no human reproductive safety data exists. AND THE REASON DEVELOPMENT ENDED WAS EFFICACY, NOT TOXICITY, which is a separate fact and should not be merged with the one above. The Japanese application was withdrawn in February 2002 for insufficient efficacy. Its post-stroke depression trial in 159 patients failed its primary endpoint; the apathy result everyone quotes is a secondary analysis inside that failed trial; and the confirmatory apathy trial screened 2,514 people and randomised thirteen. BPN14770 missed both phase 3 primary endpoints in June 2026 and is not approved anywhere. Tropisetron is not approved in the United States. Aniracetam is not approved in the United States and is no longer in clinical use. Magnesium L-threonate's best independent human trial was negative. None of these has human safety data at the combinations described here, because none of the combinations has been studied.
nothing flaggedcurated roster
every pair here reads as compatible on the mechanisms the site holds. that is the absence of a known conflict, not a clearance.
5 of 9 in one basketKimera Chems; Code Sean
Fish Oil has no outlet here at all.
7 of 9 priced
2 of these carry no listed price, so there is no honest total to print; the lines above are what can actually be costed.
5 overlapssame lever, twice
interested in protocols? join the discord; that is where dosing, timing and the practical side get discussed.
the sci-wiki publishes this as a description of what these compounds do together, not as a recommendation to take them. Nothing here is medical advice.